ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
18 announcements with these filters
Genpharmasec Ltd filed its 34th Annual Report for FY 2025-26 with BSE, including the AGM notice for 29 September 2026. The report covers audited financials, board updates, and governance disclosures.
Genpharmasec Limited has re-appointed Sohan Chaturvedi as Executive Director for a 36-month term effective April 26, 2027. This change is approved by the Board.
Genpharmasec Limited has announced the closure of its share transfer books from September 23 to 29, 2026, for the 34th Annual General Meeting.
Genpharmasec Limited announced the schedule for its 34th Annual General Meeting and approved the re-appointment of Mr. Sohan Chaturvedi as Whole Time Director.
Promoter and Director Rajesh Sadhwani acquired 65,00,000 equity shares via market purchase. This increases his stake from 14.09% to 15.26% in Genpharmasec Ltd.
Promoter and Director Rajesh Sadhwani acquired 50 lakh equity shares worth Rs. 0.505 Crore in Genpharmasec Ltd via market purchase.
Promoter Rajesh Mirchumal Sadhwani acquired 50,00,000 shares (0.90%) of Genpharmasec Ltd through an open market purchase. This transaction increases the promoter group's total stake to 30.88%.
Genpharmasec Ltd has scheduled a board meeting for September 2, 2026. The meeting will primarily focus on finalizing details for the upcoming 34th Annual General Meeting.
Genpharmasec Limited has been appointed as a non-exclusive Super Stockist by Amneal Healthcare Private Limited. The agreement includes a minimum annual sales commitment of ₹75 Crore.
Genpharmasec Ltd reported revenue from operations of ₹49.7 Cr (+314.2% YoY) and a net loss of ₹0.2 Cr for Q1 FY27.
Genpharmasec Ltd scheduled a board meeting for August 11, 2026. The board will consider unaudited financial results for the quarter ended June 30, 2026.
Genpharmasec Limited filed its Annual Secretarial Compliance Report for FY 2025-26. The auditor reported full compliance with SEBI regulations, noting no material deviations or penalties.
Genpharmasec Ltd reported zero deviation in the utilization of its ₹48.45 Crore Rights Issue proceeds. The funds were deployed according to the stated objects.
Genpharmasec Ltd reported revenue from operations of ₹55.4 Cr (+295.7% YoY) and net profit of ₹1.4 Cr for Q4 FY26.
Genpharmasec Limited reported its audited standalone and consolidated financial results for fiscal year 2026. The board also re-appointed M/s. Abhishek M Agrawal & Co. as internal auditors.
Genpharmasec Limited scheduled a board meeting for May 21, 2026. Directors will consider and approve audited financial results for the fiscal year ended March 2026.
Genpharmasec Ltd (BSE: 531592) declared it does not qualify as a Large Corporate for FY 2026-27 under SEBI debt framework. The company reported zero outstanding borrowings as of March 31, 2026. Consequently, it is not required to fulfill mandatory debt market borrowing requirements.
Genpharmasec Ltd submitted its quarterly certificate under Regulation 74(5) of SEBI Regulations for the period ended March 31, 2026. The Registrar and Share Transfer Agent, Satellite Corporate Services, confirmed that no physical share certificates were received for dematerialization during the quarter. This is a routine compliance disclosure.